Psychosocial aspects of genetic counseling and testing

Seminars in Oncology Nursing

Volumn 20, Issue 3, 2004, Pages 186-195

  Vadaparampil, Susan Thomas ^a   Wey, Jennifer Permuth ^a   Kinney, Anita Yeomans ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; GENETICS; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; KAPOSI SARCOMA; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; OVARY CANCER; PARTIAL MASTECTOMY; RISK REDUCTION; SALPINGOOOPHORECTOMY; SOCIAL PSYCHOLOGY; TRANSVAGINAL ECHOGRAPHY;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; NURSE-PATIENT RELATIONS; NURSING ASSESSMENT; NURSING METHODOLOGY RESEARCH; ONCOLOGIC NURSING; OVARIAN NEOPLASMS; PATIENT EDUCATION; QUALITY OF LIFE; RISK FACTORS;

EID: 4143130277     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.soncn.2004.04.005     Document Type: Article

References (65)

1. Pasacreta J.V., Jacobs L., Cataldo J.K. Genetic testing for breast and ovarian cancer risk the psychosocial issues. Am J Nurs. 102:2002;40-48
2. Broadstock M., Michie S., Marteau T. Psychological consequences of predictive genetic testing a systematic review. Eur J Hum Genet. 8:2000;731-738
3. Lerman C., Croyle R.T., Tercyak K.P., Hamann H. Genetic testing psychological aspects and implications. J Consult Clin Psychol. 70:2002;784-797
4. Nicholas B. Molecular genetics and moral responsibility Maybe if I were working on the atom bomb I would have a different argument. Sci Eng Ethics. 5:1999;515-530
5. Lerman C., Narod S., Schulman K., et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 275:1996;1885-1892
6. Armstrong K., Calzone K., Stopfer J., Fitzgerald G., Coyne J., Weber B. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev. 9:2000;1251-1254
7. Brandt R., Hartmann E., Ali Z., Tucci R., Gilman P. Motivations and concerns of women considering genetic testing for breast cancer a comparison between affected and at-risk probands. Genet Test. 6:2002;203-205
8. Lynch H.T., Lemon S.J., Durham C., et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79:1997;2219-2228
9. Daly M., Angelos P., Bryant E., et al. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guideline. Version 1. 2003;. Available at http://nccn.org/physician_gls/indiex.html (accessed September 16, 2003)
10. Petrucelli N., Lazebnik N., Huelsman K.M., Lazebnik R.S. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2 a survey of genetic counseling practice. Genet Test. 6:2002;107-113
11. Burke W., Daly M., Garber J., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 277:1997;997-1003
12. Meiser B., Butow P.N., Barratt A.L., et al. Long-term outcomes of genetic counseling in women at increased risk of developing hereditary breast cancer. Patient Educ Couns. 44:2001;215-225
13. Croyle R.T., Smith K.R., Botkin J.R., Baty B., Nash J. Psychological responses to BRCA1 mutation testing preliminary findings. Health Psychol. 16:1997;63-72
14. Schwartz M.D., Peshkin B.N., Hughes C., Main D., Isaacs C., Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol. 20:2002;514-520
15. Hallowell N., Foster C., Ardern-Jones A., Eeles R., Murday V., Watson M. Genetic testing for women previously diagnosed with breast/ovarian cancer examining the impact of BRCA1 and BRCA2 mutation searching. Genet Test. 6:2002;79-87
16. Hughes C., Lerman C., Schwartz M., et al. All in the family evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet. 107:2002;143-150
17. Vallon-Christersson J., Cayanan C., Haraldsson K., et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet. 10:2001;353-360
18. Fleming M.A., Potter J.D., Ramirez C.J., Ostrander G.K., Ostrander E.A. Understanding missense mutations in the BRCA1 gene an evolutionary approach. Proc Natl Acad Sci U S A. 100:2003;1151-1156
19. Shaw de Paredes E., Marsteller L.P., Eden B.V. Breast cancers in women 35 years of age and younger mammographic findings. Radiology. 177:1990;117-119
20. Brekelmans C.T., Seynaeve C., Bartels C.C., et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 19:2001;924-930
21. Peer P.G., Verbeek A.L., Straatman H., Hendriks J.H., Holland R. Age-specific sensitivities of mammographic screening for breast cancer. Breast Cancer Res Treat. 38:1996;153-160
22. Chakraborty R., Sankaranarayanan K. Mutations in the BRCA1 gene implications of inter-population differences for predicting the risk of radiation-induced breast cancers. Genet Res. 72:1998;191-198
23. Brenner D.J., Sawant S.G., Hande M.P., et al. Routine screening mammography how important is the radiation-risk side of the benefit-risk equation? Int J Radiat Biol. 78:2002;1065-1067
24. Friedenson B. Is mammography indicated for women with defective BRCA genes? Implications of recent scientific advances for the diagnosis, treatment, and prevention of hereditary breast cancer. Med Gen Med. 2:2000;E9
25. Woolas R.P., Xu F.J., Jacobs I.J., et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 85:1993;1748-1751
26. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388
27. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer an overview of the randomised trials. Lancet. 351:1998;1451-1467
28. Narod S.A., Brunet J.S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 356:2000;1876-1881
29. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2 National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 286:2001;2251-2256
30. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 339:1998;424-428
31. Modan B., Hartge P., Hirsh-Yechezkel G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 345:2001;235-240
32. Ursin G., Henderson B.E., Haile R.W., Pike M.C., Zhou N., Diep A., Bernstein L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res. 57:1997;3678-3681
33. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 345:2001;159-164
34. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 340:1999;77-84
35. Weber B., Punzalan, Eisen A., et al. Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers. (abstr) Am J Hum Genet. 67:(s2):2000;59
36. Rebbeck T.R., Levin A.M., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 91:1999;1475-1479
37. Botkin J.R., Smith K.R., Croyle R.T., et al. Genetic testing for a BRCA1 mutation prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet. 118A:2003;201-209
38. Lerman C., Hughes C., Croyle R.T., et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med. 31:2000;75-80
39. Stefanek M., Hartmann L., Nelson W. Risk-reduction mastectomy clinical issues and research needs. J Natl Cancer Inst. 93:2001;1297-1306
40. Bleiker E.M., Hahn D.E., Aaronson N.K. Psychosocial issues in cancer genetics-current status and future directions. Acta Oncol. 42:2003;276-286
41. Swisher E.M., Babb S., Whelan A., Mutch D.G., Rader J.S. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med. 46:2001;87-94
42. Lerman C., Croyle R.T. Genetic testing for cancer predisposition. behavioral science issues. J Natl Cancer Inst Monogr. 17:1995;63-66
43. American College of Obstetrics and Gynecology. Tamoxifen and the prevention of breast cancer in high-risk women. ACOG Committee Opinion, 1999. Int J Gynaecol Obstet. 68:2000;73-75
44. Tewari K., Bonebrake R.G., Asrat T., Shanberg A.M. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet. 350:1997;183
45. Iguchi T., Hirokawa M., Takasugi N. Occurrence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology. 42:1986;1-11
46. Chamness G.C., Bannayan G.A., Landry L.A. Jr, Sheridan P.J., McGuire W.L. Abnormal reproductive development in rats after neonatally administered antiestrogen (tamoxifen). Biol Reprod. 21:1979;1087-1090
47. Gotlieb W.H., Baruch G.B., Friedman E. Prophylactic oophorectomy clinical considerations. Semin Surg Oncol. 19:2000;20-27
48. Gao Q., Tomlinson G., Das S., et al. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet. 107:2000;186-191
49. Neuhausen S.L. Ethnic differences in cancer risk resulting from genetic variation. Cancer. 86:1999;2575-2582
50. Lynch H.T., Drouhard T.J., Schuelke G.S., Biscone K.A., Lynch J.F., Danes B.S. Hereditary nonpolyposis colorectal cancer in a Navajo Indian family. Cancer Genet Cytogenet. 15:1985;209-213
51. Makridakis N.M., Ross R.K., Pike M.C., et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 354:1999;975-978
52. Chen W.Y., Garber J.E., Higham S., et al. BRCA1/2 genetic testing in the community setting. J Clin Oncol. 20:2002;4485-4492
53. American Cancer Society. Cancer prevention & early detection facts and figures-2003. 2002;American Cancer Society, Atlanta, GA. ACS Publication No. 8600.03
54. Donovan K.A., Tucker D.C. Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. J Behav Med. 23:2000;15-36
55. Glanz K., Grove J., Lerman C., Gotay C., Le Marchand L. Correlates of intentions to obtain genetic counseling and colorectal cancer gene testing among at-risk relatives from three ethnic groups. Cancer Epidemiol Biomarkers Prev. 8:1999;329-336
56. Meiser B., Eisenbruch M., Barlow-Stewart K., Tucker K., Steel Z., Goldstein D. Cultural aspects of cancer genetics setting a research agenda. J Med Genet. 38:2001;425-429
57. Guidry J.J., Matthews-Juarez P., Copeland V.A. Barriers to breast cancer control for African-American women the interdependence of culture and psychosocial issues. Cancer. 97:2003;318-323
58. Furr L.A. Perceptions of genetics research as harmful to society differences among samples of African-Americans and European-Americans. Genet Test. 6:2002;25-30
59. Matthews A., Cummings S., Thompson S., Wohl V., List M., Olopade O. Genetic testing of African Americans for inherited cancers use of focus groups to determine factors contributing to participation. J Psychosocial Oncol. 18:2000;1-19
60. Thompson H.S., Valdimarsdottir H.B., Duteau-Buck C., et al. Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev. 11:2002;1579-1585
61. Penchaszadeh V.B. Genetic counseling issues in Latinos. Genet Test. 5:2001;193-200
62. Burhansstipanov L., Bemis L.T., Dignan M.B. Native American cancer education genetic and cultural issues. J Cancer Educ. 16:2001;142-145
63. Peterson S.K. Oncology nurse's knowledge, practice, and educational needs regarding cancer genetics. Am J Med Genet. 98:2001;3-12
64. Baty B.J., Kinney A.Y., Ellis S.M. Developing culturally sensitive cancer genetics communication aids for African Americans. Am J Med Genet. 118A:2003;146-155
65. Resnicow K., Baranowski T., Ahluwalia J.S., Braithwaite R.L. Cultural sensitivity in public health defined and demystified. Ethn Dis. 9:1999;10-21